Back to Search Start Over

Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study

Authors :
Hill, Joshua A.
Martens, Michael J.
Young, Jo-Anne H.
Bhavsar, Kavita
Kou, Jianqun
Chen, Min
Lee, Lik Wee
Baluch, Aliyah
Dhodapkar, Madhav Vishnu
Nakamura, Ryotaro
Peyton, Kristin
Shahid, Zainab
Armistead, Paul M.
Westervelt, Peter
McCarty, John M.
McGuirk, Joseph P
Hamadani, Mehdi
DeWolf, Susan
Hosszu, Kinga
Sharon, Elad
Spahn, Ashley
Toor, Dr. Amir A.
Waldvogel, Stephanie
Greenberger, Lee M.
Auletta, Dr. Jeffery J.
Horowitz, Mary M.
Riches, Marcie L.
Perales, Miguel-Angel
Source :
Transplantation and Cellular Therapy; February 2024, Vol. 30 Issue: 2, Number 2 Supplement 1 pS82-S83, 2p
Publication Year :
2024

Abstract

We previously reported the immunogenicity of SARS-CoV-2 vaccination within the first year after allogeneic hematopoietic cell transplant (HCT) from CIBMTR SC21-07/BMT CTN 2101. We herein report updated results from the full allogeneic HCT cohort in addition to the autologous HCT and CAR-T cell therapy cohorts.

Details

Language :
English
ISSN :
26666375 and 26666367
Volume :
30
Issue :
2, Number 2 Supplement 1
Database :
Supplemental Index
Journal :
Transplantation and Cellular Therapy
Publication Type :
Periodical
Accession number :
ejs65462761
Full Text :
https://doi.org/10.1016/j.jtct.2023.12.134